

# Accepted Manuscript

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-TNF Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials

J.L. Jones, G.G. Kaplan, L. Peyrin-Biroulet, L. Baidoo, S. Devlin, G.Y. Melmed, D. Tanyingoh, L. Raffals, P. Irving, P. Kozuch, M. Sparrow, F. Velayos, B. Bressler, A. Cheifetz, J.-F. Colombel, C.A. Siegel



PII: S1542-3565(15)00910-6  
DOI: [10.1016/j.cgh.2015.06.034](https://doi.org/10.1016/j.cgh.2015.06.034)  
Reference: YJCGH 54358

To appear in: *Clinical Gastroenterology and Hepatology*

Accepted Date: 20 June 2015

Please cite this article as: Jones J, Kaplan G, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed G, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel J-F, Siegel C, Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-TNF Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials, *Clinical Gastroenterology and Hepatology* (2015), doi: 10.1016/j.cgh.2015.06.034.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All studies published in *Clinical Gastroenterology and Hepatology* are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.

## Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-TNF Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials

Jones JL<sup>1</sup>, Kaplan GG<sup>2</sup>, Peyrin-Biroulet L<sup>3</sup>, Baidoo L<sup>4</sup>, Devlin S<sup>2</sup>, Melmed GY<sup>5</sup>, Tanyingoh D<sup>2</sup>, Raffals L<sup>6</sup>, Irving P<sup>7</sup>, Kozuch P<sup>8</sup>, Sparrow M<sup>9</sup>, Velayos F<sup>10</sup>, Bressler B<sup>11</sup>, Cheifetz A<sup>12</sup>, Colombel J-F<sup>13</sup>, Siegel CA<sup>14</sup>

### Affiliations:

1. Dalhousie University, Halifax,, Canada
2. University of Calgary, Calgary, Canada
3. Inserum U954 and Université de Lorraine, , Nancy, France
4. University of Pittsburgh, Pittsburgh, United States
5. Cedars-Sinai Medical Center, Los Angeles, California, United States
6. Mayo Clinic, Rochester, Minnesota, United States
7. Guy's and St. Thomas' Hospitals, London, United Kingdom
8. Jefferson University, Philadelphia, United States
9. The Alfred Hospital, Melbourne, Australia
10. University of California San Francisco, San Francisco, United States
11. University of British Columbia, Vancouver, Canada
12. Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
13. Icahn School of Medicine at Mount Sinai, New York, Unite States
14. Dartmouth-Hitchcock Medical Center, Lebanon, United States

### Author's roles:

Jones: first author, study design, data abstraction, analysis & interpretation, writing and manuscript development

Kaplan: Study design, data analysis and manuscript development

Peyrin-Biroulet & Colombel: Study design, manuscript review and development

Baidoo & Devlin: data abstraction, manuscript review

Melmed, Raffals, Irving, Kozuch, Sparrow, Velayos, Bressler: Manuscript review and contributions to development

Siegel: Senior author, data anlysis & interpretation, study design, manuscript preparation and review

### Conflict of interest statements

- *Jones JL* has served as a speaker for Jansen, Merck, Schering-Plough, Abbot and Abbvie and has participated in advisory boards for Janssen, Abbott and Takeda.
- *Kaplan GG* has served as a speaker for Jansen, Merck, Schering-Plough, and Abbott. He has participated in advisory board meetings for Jansen and Abbott. Dr. Kaplan has received research support from Merck, Abbott, and Shire.
- *Peyrin-Biroulet L* has received consulting fees from Merck, Abbott, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Shire, Therakos, Pharmacosmos, Pilège, BMS, UCB-pharma, Hospira, Celltrion, Takeda, Boehringer-Ingelheim, Lilly. He has received lecture fees from Merck, Abbott, Janssen, Ferring, Norgine, Tillots, Vifor, Therakos, HAC-pharma.
- *Baidoo L* has no conflicts of interest to delcare
- *Devlin S* has served on speaker's and as a consultant bureau for Takeda, Janssen, and abbvie.

Download English Version:

<https://daneshyari.com/en/article/3281567>

Download Persian Version:

<https://daneshyari.com/article/3281567>

[Daneshyari.com](https://daneshyari.com)